{"id":"japanese-encephalitis-purified-inactivated-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL6068364","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) Japanese encephalitis virus particles that trigger both humoral and cell-mediated immune responses without causing disease. Upon vaccination, the immune system recognizes viral antigens and generates protective antibodies and memory T cells that prevent infection or reduce disease severity upon exposure to live virus.","oneSentence":"This inactivated vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:32.821Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Japanese encephalitis in at-risk populations and travelers"}]},"trialDetails":[{"nctId":"NCT02963909","phase":"PHASE1","title":"A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-01","conditions":"Zika Virus Infection","enrollment":75},{"nctId":"NCT00594958","phase":"PHASE3","title":"Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2006-09","conditions":"Japanese Encephalitis","enrollment":639},{"nctId":"NCT00605085","phase":"PHASE3","title":"Safety and Tolerability of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-10","conditions":"Japanese Encephalitis","enrollment":2675},{"nctId":"NCT00604708","phase":"PHASE3","title":"Immunogenicity Study of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-09","conditions":"Japanese Encephalitis","enrollment":867},{"nctId":"NCT04223037","phase":"PHASE3","title":"Purified Inactivated Japanese Encephalitis Vaccine","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2015-09-01","conditions":"Japanese Encephalitis Virus Disease","enrollment":1050},{"nctId":"NCT01041573","phase":"PHASE3","title":"Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-03","conditions":"Encephalitis","enrollment":1869},{"nctId":"NCT01047839","phase":"PHASE3","title":"Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-01","conditions":"Encephalitis","enrollment":100},{"nctId":"NCT03971058","phase":"PHASE4","title":"Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2019-03-01","conditions":"Japanese Encephalitis Vaccine","enrollment":64},{"nctId":"NCT01398540","phase":"PHASE4","title":"Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2010-11","conditions":"Humoral and Cellular Immune Responses","enrollment":60},{"nctId":"NCT00596102","phase":"","title":"Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-10","conditions":"Japanese Encephalitis","enrollment":3258},{"nctId":"NCT00595465","phase":"PHASE3","title":"Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2007-12","conditions":"Japanese Encephalitis","enrollment":389},{"nctId":"NCT00596271","phase":"PHASE3","title":"Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-09","conditions":"Japanese Encephalitis","enrollment":192},{"nctId":"NCT00595790","phase":"PHASE3","title":"Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-09","conditions":"Japanese Encephalitis","enrollment":374},{"nctId":"NCT00595270","phase":"PHASE3","title":"Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-10","conditions":"Japanese Encephalitis","enrollment":349},{"nctId":"NCT00694460","phase":"PHASE2","title":"Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-08","conditions":"Rabies, Japanese Encephalitis, Pre-Exposure Prophylaxis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Japanese Encephalitis purified inactivated vaccine","genericName":"Japanese Encephalitis purified inactivated vaccine","companyName":"Valneva Austria GmbH","companyId":"valneva-austria-gmbh","modality":"Biologic","firstApprovalDate":"","aiSummary":"This inactivated vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus. Used for Prevention of Japanese encephalitis in at-risk populations and travelers.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}